Good afternoon, ladies and gentlemen. I would like to welcome everyone to the Lantheus Holdings Third Quarter 2017 Earnings Conference Call. This is your operator for today’s call. [Operator Instructions] This call is being recorded for replay purposes. A replay of the audio webcast will be available in the Investors section of the company’s website approximately two hours after completion of the call through December 2, 2017. I would now like to turn the call over to your host for today, Gary Santo, Head of Capital Markets and Investor Relations.

Thank you, operator. Good afternoon, everyone, and thank you for joining us for Lantheus Holdings Third Quarter 2017 Earnings Conference Call. With me on the call today are Mary Anne Heino, our President and Chief Executive Officer; and Jack Crowley, our Chief Financial Officer. Please note that earlier this afternoon, we issued a press release, also filed with the Securities and Exchange Commission under Form 8-K, reporting our third quarter 2017 results. Later this afternoon, we anticipate filing our Form 10-Q with the SEC for the quarter ended September 30, 2017. You can find these documents as well as a replay of this call in the Investors section of our website at www.lantheus.com. Remarks that we make today regarding future expectations, plans and prospects for the company constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, which we disclose in more detail in the Risk Factors section of our Forms 10-K and 10-Q. We remind you that any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may update any such forward-looking statements in the future, we specifically disclaim any obligation to do so. Finally, on today’s call, we will reference certain non-GAAP financial measures with respect to our performance. We use these non-GAAP indicators for financial and operational decision making and as a means to evaluate our performance. Reconciliations to GAAP metrics for EBITDA, adjusted EBITDA, adjusted operating income, adjusted net income, adjusted net income per diluted common share, and free cash flow are set forth in our earnings press release. Of particular note, these tables include the reconciliation of our GAAP net income to adjusted EBITDA, a metric we consider to be particularly relevant at this time, due to the variability of our technology transfer activities and related costs. Mary Anne will begin her comments today with a high-level review of our third quarter accomplishments. After which, Jack will provide a more detailed review of our financial performance during the quarter. Mary Anne will then provide additional and closing comments. With that, I will now turn the call over to Mary Anne.

Thank you, Gary, and welcome to everyone joining us today on our conference call. Performance for the quarter was once again strong with third quarter 2017 revenue and adjusted EBITDA results, both exceeding the high end of our guidance for the quarter. Total worldwide revenues for the quarter grew approximately 9% compared to the same period one year ago. Revenue for our flagship imaging agent, DEFINITY, grew approximately 16% compared to the third quarter of 2016, as a result of higher unit volumes. Revenue growth in our TechneLite product was approximately 7% on a year-over-year basis, while Xenon revenues for the quarter were up approximately 16% compared to the third quarter of 2016, both primarily attributable to higher volumes. These strong revenue results during the quarter yielded over a 100% improvement in our net income and an increase of approximately 21% in our adjusted EBITDA when compared to the third quarter of 2016. Combined with the strength of our balance sheet, these results will enable us to make additional investments in strategic initiatives in the future, while continuing to drive positive bottom line results. I now invite Jack to provide a more detailed review of our third quarter results as well as our updated guidance for the year. After which, I will provide an update on some recent events of note and closing comments. Jack?

Thanks, Mary Anne, and good afternoon, everyone. As a reminder, the tables included in today’s press release include a reconciliation of our GAAP results to the as-adjusted non-GAAP performance I’ll be covering with you today. I’ll begin my comments by focusing on our third quarter results as compared to the third quarter of 2016, followed by our revised full year guidance. In the third quarter, Lantheus delivered $79.9 million in worldwide revenue, an increase of 9.4% as compared to the third quarter of 2016. DEFINITY continued its strong performance with worldwide revenues totaling $37.7 million for the quarter, an increase of 15.7% over last year. TechneLite revenue in the third quarter was $26.4 million, an increase of 7.4% over the prior year, while Xenon revenue for the third quarter was $7.7 million, an improvement of 15.7%. Finally, revenue from our other product category was $8.1 million for the third quarter, down from $9.2 million one year ago. Excluding the 2016 impact from our Australian radiopharmacy business, which we divested in August of 2016, as well as the impact of Hurricane Maria on our Puerto Rico operations, revenue from our other product category remained relatively flat. Moving below the revenue line, our third quarter 2017 gross profit margin, excluding technology transfer activities, which we referred to in our reconciliations as new manufacturing costs, totaled approximately 50.2%, an increase of 300 basis points over the prior year. This improvement was once again attributable to the increased contribution of our higher-margin products, including the impact of Xenon cost savings generated by the addition of processing and finishing capabilities at our Billerica facility late last year. Operating expenses were $25.7 million in the third quarter of 2017, an increase of $4.1 million compared to last year. This was largely attributable to $1.9 million in…

Thank you, Jack. I would now like to spend a few minutes discussing some key developments that have occurred since our last earnings call. In early July, the Centers for Medicare and Medicaid Services, or CMS, released their proposed 2018 Medicare payment rules for Hospital Outpatient Prospective Payment System, or HOPPS. The 2018 proposed rules include significant changes to reimbursement rates for a number of procedures, including contrast-enhanced echo. As in previous years, during the open comment period immediately following the release of the proposed rules, the medical community together with industry leaders, including Lantheus, worked to inform CMS of any unintended consequences inherent in their proposal. The final CMS HOPPS 2018 rules were published yesterday. On an absolute basis, CMS slightly raised reimbursement levels for both contract-enhanced echos and noncontrast-enhanced echos. On a relative basis, these rates are consistent with 2017 rates. Lantheus remains committed to strong advocacy for appropriate reimbursement of contrast-enhanced echo procedures as well as for the cost effectiveness of the use of imaging agents such as DEFINITY. While on the subject of DEFINITY, during our last call last quarter, I spoke of our multifaceted next generation programs. We are pleased to report that in October, we received approval for a new method of use patent for DEFINITY, which was listed in the Orange Book. This patent will expire in 2037. For competitive reasons, I will not offer any additional details at this time about our program. I can say, however, that we continue to make good overall progress on our next generation programs, and we’ll report more on that progress in early 2018. From a worldwide perspective, our DEFINITY China program continues to advance with first patients now enrolled in both the cardiac and liver studies. We expect enrollment in the kidney study before year-end.…

[Operator Instructions] And our first question comes from Anthony Petrone with Jefferies.

Couple of questions on DEFINITY, specifically, on the reimbursement announcement today. And then maybe a follow-up also on just patent expirations for DEFINITY. First on the reimbursement announcement. Do you get the sense that there was some concern amongst hospitals about the proposal? And now that we’re getting, sort of, a final ruling that essentially keeps the current reimbursement structure in place, do you see this potentially as a tailwind to growth for DEFINITY heading into 2018?

Anthony, it’s Mary Anne, and thank you for joining the call. And I’ll answer your question, which, again, is an opinion that I’ll offer. I would not say that there was widespread awareness at a hospital level about these rules, and I’ll explain why. These rules are included, the proposed rates, in a document that is well over 800 pages and covers every procedure that is performed in the outpatient setting. And so if you think about a hospital and all of the other activities they undergo, I don’t think there is line item detail awareness. Having said that, there are a group of industry participants, Lantheus included, who paid very careful attention to that. And we were very quick and active and cohesive in our communications to CMS about what we felt was appropriate reimbursement for procedures that offer valuable insight and information in the diagnostic procedures that are involved, and I think that may have been contributable to CMS’ final decision. I would say also, just for clarity, this is a process that happens every year. So the same process that we saw this year where there is an initial announcement on proposed rates for the upcoming year, followed by a common period before the publication of final reimbursement rates, replicates on an annual basis, and we are very involved in it and very attentive to it every year.

And follow-up on DEFINITY would be, just as it relates to patent expirations in sort of the 2019 to 2021 era. Is – are there any plans for, I guess, an enhancement of the IP position around DEFINITY and/or sort of reformulation efforts for that product? And then, the last one from me would be just on the radiopharmaceutical side of the business. Just any update on contract renegotiations heading into the end of the year?

So Anthony, I will answer an affirmative strong yes to your question about whether we intend to continue our efforts to protect the intellectual property of DEFINITY and of the other assets that are in our next generation programs. I think one of the demonstrations of that is this recently awarded Orange Book patent, which is a method of use patent, which dates out now to 2037, that is added to the armamentarium of patents and intellectual property that we protect for our products, and we will continue those efforts very strongly. If you would like to ask your question more specifically about nuclear contracting, I did announce on the call that we now have an extended contract with Cardinal Health through 2018. The fourth radiopharmacy chain customer that we historically had a relationship with, which is Triad Isotopes, their contract – our current contract with them expires at the end of December. We remain in active dialogue with them to agree to what our relationship will be in 2018.

And our next question comes from Larry Biegelsen with Wells Fargo.

Bunch of questions here. Let me just start with some housekeeping ones. Mary Anne, do you feel like your Q3 results were negatively impacted by the hurricanes in the quarter?

Larry, thank you for joining. As Jack mentioned, the impact of sales or sales loss in those areas was such that it didn’t change our performance for the quarter. And those sales – those particular sales were included in our other category. The other item that was impacting that category was the year-over-year difference that was drawn by the sale of our radiopharmacy in Australia. As we look forward, we’re certainly aware that the pace and number – absolute number of medical procedures being conducted in Puerto Rico has not yet returned to pre-storms levels, but we’re confident over time it will. And as you can see with our guidance, we actually took our guidance up for the year. So certainly, we did not see enough of an impact to have pause or cause to take our guidance down.

And then second, day count. Could you remind us if there was a difference in day count in the third quarter on a year-over-year basis and the fourth quarter, is there a difference in day count?

Are you talking about working business days?

Yes.

The number of shipping business days Q4 is equal to that of Q3. And for the business year 2017, that equals 49 for each quarter.

So on a year-over-year basis, in the third quarter of this year, there was no difference from the third quarter of last year. And in the fourth quarter of this year, there’s no difference in the fourth quarter of last year?

So Larry, there is a slight difference. As compared year-over-year 2017 Q3 versus 2016 Q3, 2017 has one less shipping day. For the same period in Q4 year-over-year, it’s an equal number of shipping days, 49 in each quarter.

I got it. And then my real question. So I mean, one thing that I noticed this quarter is TechneLite and Xenon continue to grow. You talked about contracted volumes. Can you talk about the sustainability of the growth of Xenon and TechneLite?

That’s two different questions, Larry. And I’ll speak to them – I’ll make a statement that applies to both, and then I’ll speak to them separately. The statement that applies to both is that our contracting strategy and our sale strategy for our nuclear medicine products is one that’s very driven – very much driven on a volume margin basis. And so we look continually at what’s the best volume of those products is to flow through our campus, of course, backed by market demands, to optimize our operating costs and, therefore, the margin for those products. I think you see some of those results through 2017 already. And in fact 2017 volumes for both of those products are higher than the corresponding periods in 2016. As we look out to 2018, it’s not something that you’ll hear me speaking to specifically other than to say our continued attention will be to margins. Margin at above the nuclear medicine kind of products business level as well as to the company level, and our contracting efforts will reflect that.

Right, well, that takes me to my 2018 question. Maybe this year the guidance implies about 7% year-over-year growth on the top line. I think the EBITDA margin, if I’m doing the math right, the midpoint, it’s 26.9% versus the 25.9% reported last year. So can you help us think about some of the puts and takes for 2018? I know you’re not giving guidance, but things we should be aware of on the top and bottom line?

Larry, it’s Jack. I’ll take that. And – no, I mean, we’ll give the guidance at our next call when we provide the full year ‘18 guidance. And, obviously, the puts and takes, some of the things that have impacted our adjusted EBITDA margin is, obviously, the product mix, our continued work to get more efficiencies on our campus and then sometimes the timing of projects has lead to some of that fluctuation in those quarter-over-quarter. So we’ll give more guidance on that when we address the ‘18 guidance.

Fair enough. And then the Cardinal contract, Mary Anne. Any change to the terms there? I know last time you had a new Cardinal contract, there were changes to the terms. Anything you can share with us? And I have one other follow-up.

There were changes in the terms, but it’s a multiproduct contract. So I’m not going to be specific to changes at an individual product level.

So there’s nothing – I mean – go ahead, I’m sorry.

We’re really pleased with the contracts.

Okay. Fair enough. And then just on the pipeline, Mary Anne, just – let me just rattle up a couple of things you didn’t touch on. F18 Phase III trial, when do you think that’s going to start? I know it’s in GE’s hands, I believe. DEFINITY China, can you just walk us through – remind us the steps and when that product could come to market? And that’s it for me.

The F18, you’re right, Larry. The F18 trial – the second F18 trial is in GE Healthcare’s hands, very capable hands. And we’ve been very pleased with the relationship there and with the orderly, kind of, progress of not only transition of information to them, but their ability to kind of incorporate that information and move forward. I think it’s fair to say we expect to see that trial begin in Q1 of ‘18. But we’ll have more – we’ll share more information as we have it and as we gain approval from GE to share it with you because, again, that trial is in their hands. China is something I can speak to directly because they are – our trial is being conducted there. As I mentioned, we have seen patient starts in both the cardiac and the liver studies. And as a reminder, there are – essentially there’s 4 small confirmatory studies that will take place in China as part of the approval process. And they’re small, and they’re confirmatory. The four different studies are cardiac, and then liver and kidney because there, they split apart the, kind of, the definition of abdominal into those two organs. And the fourth one is a PK study, which is also required by the – one of the regulatory offices in China for what would be considered an imported drug. Those trials are all well defined. We expect to see the start of the first patient in for the kidney trial as well by the end of this year. Once they start, unlike Phase III trials in the U.S. regulatory process, these are small and confirmatory studies, so it’s fair to say that they would be completed within 6 months with data fully available from them.

And our next question comes from Erin Wright with Crédit Suisse.

A follow-up to the, I guess, more favorable reimbursement news out last night. I guess, how should we think about your overall exposure and sensitivity to these types of reimbursement dynamics and what you’ve seen historically? I guess, how that really impacts utilization or demand trends?

Yes, Erin. Thanks for joining the call. And I think your questions are really good one. I’m really pleased to answer it. I think we should as participants in health care delivery as well as being patients in the same health care delivery system in the United States, we should all be constantly aware that there is pressure for more efficient use of health care dollars and for demands for proof of value for the health care dollars that are spent. And we’re happy to take that challenge with our products and with the diagnostic exams that our products service. And I think the work we did over the summer with our peers, and when I say peers here, I mean, not only the companies who are competitive in our space, but I mean, physicians from medical societies and from other parts of health care – the health care delivery chain, and our collective efforts to CMS to demonstrate the value offered by the use of contract agents where needed in these medical procedures, was well heard. And therefore, the value was held when the final rates were stated. I would expect us to be given that challenge every year, and I see those – our obligation to continually prove that the use of our products and those services deliver the value above and beyond whatever cost there is to administer it.

Okay. Great. And then kind of switching gears here a little bit. I mean, can we speak to, kind of, your priorities at the moment from a capital deployment standpoint? And can you, I guess, give us an update on your business development efforts at the moment?

Erin, it’s Jack. I’ll take that. So as we’ve talked about, one of the places we’ve been and worked very hard to get to is a really strong liquidity position. We do continue to have a good amount of cash in the balance sheet and the $75 million revolver gives us flexibility. We do think the improved stock price gives us additional dry powder, if you will. And what I can say is the business development activities are ongoing at a very good and measured pace, and we do pay attention to it. We’re not locking ourselves in any particular strategy, but we are open and focused on a number of different fronts.

I think also it’s fair to say you’re going to hear more about that in early ‘18, Erin.

Okay. Great. That’s fair. I guess, just what would be kind of a big opportunity versus small? Or do you have sort of a sweet spot in terms of size?

Yes, I would say we don’t really necessarily have a definitive sweet spot. I mean, we want to be opportunistic. I mean, I know you’ve heard this before so don’t chuckle, but we worked very hard to get into the place we are at, and so we want to be very careful and purposeful in the deployment of that capital. So as part of that strategy, we are evaluating a number of options, and we’re not really locking ourselves into – Mary Anne has talked in the past about small tuck-in acquisitions or more significant acquisitions or other partnerships. I mean, we’re really evaluating a number of things across a wide range of size, if you will.

I would also share that we have active conversations out in the marketplace – out in different marketplaces, in fact, to ensure that we’re thinking about all the different possibilities of what constitutes a good deal, it’s not only by size, but by fit for us.

Thank you, ladies and gentlemen. This concludes today’s conference. Thank you for participating. You may now disconnect.